Atossa Therapeutics (ATOS) EBT (2011 - 2026)

Atossa Therapeutics (ATOS) has reported EBT for 16 consecutive years, with -$8.5 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBT fell 0.81% year-over-year to -$8.5 million in Q2 2026; TTM through Jun 2026 was -$37.7 million, a 31.31% decrease from a year earlier, with the FY2025 full-year figure at -$34.8 million, down 36.33% from the prior year.
• EBT was -$8.5 million for Q2 2026 at Atossa Therapeutics, up from -$9.6 million in the prior quarter.
• Over five years, EBT peaked at -$4.8 million in Q1 2022 and troughed at -$10.9 million in Q4 2025.
• A 5-year average of -$7.5 million and a median of -$7.4 million in 2022 frame the typical range for EBT.
• Across the five-year window, EBT jumped 38.46% in 2024 and tumbled 72.32% in 2025, its largest moves.
• Over 5 years, EBT stood at -$7.5 million in 2022, then fell by 3.51% to -$7.8 million in 2023, then grew by 18.15% to -$6.3 million in 2024, then plunged by 72.32% to -$10.9 million in 2025, then climbed by 22.36% to -$8.5 million in 2026.
• The last three EBT figures came in at -$8.5 million (Q2 2026), -$9.6 million (Q1 2026), and -$10.9 million (Q4 2025), per Business Quant data.